0000078003false00000780032024-07-092024-07-090000078003us-gaap:CommonStockMember2024-07-092024-07-090000078003pfe:NotesDue20271.000Member2024-07-092024-07-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 9, 2024

PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170
(State or other(Commission File(I.R.S. Employer
jurisdiction ofNumber)Identification No.)
incorporation)  
66 Hudson Boulevard East10001-2192
New York, New York (Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code:
(212) 733-2323

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐




Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company. The Company has initiated an external search for a new Chief Scientific Officer. Dr. Dolsten will continue to serve in his current position until his successor is in place and any necessary transition is complete. It is anticipated that Dr. Dolsten will remain with Pfizer through at least February 28, 2025.









SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 PFIZER INC.
   
   
Dated: July 10, 2024By:/s/ Margaret M. Madden
 Margaret M. Madden
  Senior Vice President and Corporate Secretary
  Chief Governance Counsel
   


v3.24.2
Cover Page
Jul. 09, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Jul. 09, 2024
Entity Registrant Name PFIZER INC
Entity Incorporation, State or Country Code DE
Entity File Number 1-3619
Entity Tax Identification Number 13-5315170
Entity Address, Address Line One 66 Hudson Boulevard East
Entity Address, City or Town New York,
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10001-2192
City Area Code 212
Local Phone Number 733-2323
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0000078003
Common Stock [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $.05 par value
Trading Symbol PFE
Security Exchange Name NYSE
Notes Due 2027, 1.000% [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 1.000% Notes due 2027
Trading Symbol PFE27
Security Exchange Name NYSE
Pfizer (NYSE:PFE)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Pfizer Charts.